Evening Group-Rush University Medical Center-Crohn disease-ulcerative colitis

This refers to the evening dosing arm of a chronotherapy clinical trial (NCT03076307) conducted by Rush University Medical Center for the treatment of Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. The study investigated whether the timing of administration (specifically between 6:00 pm and 11:00 pm) of thiopurine immunosuppressants, namely azathioprine and 6-mercaptopurine (6-MP), affects drug metabolite profiles and clinical outcomes. Azathioprine is a prodrug that is converted into 6-mercaptopurine; both function as antimetabolites that inhibit purine nucleotide synthesis, thereby interfering with DNA and RNA synthesis and suppressing the proliferation of T-lymphocytes involved in the inflammatory response. The trial aimed to determine if evening dosing, relative to morning dosing, optimized the levels of active 6-thioguanine nucleotides (6-TGN) while minimizing toxic 6-methylmercaptopurine (6-MMP) metabolites.

Other names

Evening GroupChronotherapy in Inflammatory Bowel Disease - Evening Arm